What is the current market size?

The Cyanocobalamin Injection market size was valued at USD 1.2 billion in 2023, driven by rising demand for vitamin B12 supplementation in chronic deficiency cases.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing geriatric populations and prevalence of malabsorption disorders.

What are the key growth drivers?

Key drivers include rising awareness of vitamin B12 benefits, growing incidence of anemia, and expanding applications in neurological and psychiatric treatments.

What challenges does the market face?

Challenges include stringent regulatory hurdles, side effects like hypersensitivity, and stringent quality control requirements for injectable drugs.

Which regions lead the market?

North America and Europe dominate the market, while the Asia-Pacific region is emerging as a high-growth area due to improving healthcare infrastructure.

Who are the top companies?

Leading players include Sanofi, Roche, Fresenius Kabi, and Mylan, leveraging R&D and strategic partnerships to maintain market share.

What future opportunities exist?

Future opportunities lie in over-the-counter formulations, nutraceutical applications, and personalized dosing for chronic deficiency management.

How is technology impacting the market?

Advancements in pre-filled syringes and subcutaneous delivery systems are improving patient compliance and expanding market accessibility.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA mandate rigorous clinical trials for safety and efficacy, ensuring high standards for Cyanocobalamin Injection approvals.

What is the future outlook?

The future outlook remains optimistic, with growing healthcare spending, rising chronic disease prevalence, and innovation in drug delivery technologies.

Cyanocobalamin Injection Market Potential & Strategic Outlook 2033

Cyanocobalamin Injection by Application (Hospitals, Clinics, Others), by Types (Vitamins, Supplements), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cyanocobalamin Injection Market Overview

The Cyanocobalamin Injection market represents a critical segment of the pharmaceutical industry, addressing vitamin B12 deficiency treatment through parenteral administration. Cyanocobalamin, a synthetic form of cobalamin, is widely prescribed for conditions like anemia, neurological disorders, and metabolic deficiencies. As a key growth outlook driver, the rising prevalence of B12 deficiency—exacerbated by aging populations, dietary shifts, and gastrointestinal disorders—fuels demand for injectable formulations. The Cyanocobalamin Injection market size is projected to expand significantly, supported by advancements in drug delivery systems and the increasing adoption of generic pharmaceuticals.

The Cyanocobalamin Injection market is estimated at USD 1.3 billion in 2025, with a compound annual growth rate (CAGR) of 6.8% anticipated from 2026 to 2033. Macro drivers include regulatory approvals for biosimilars, rising healthcare expenditure in emerging economies, and the shift toward outpatient care models. Key forces shaping the industry include technology shifts in precision dosing and supply-chain dynamics favoring cost-effective manufacturing. North America remains the largest regional market, while Asia-Pacific is the fastest-growing region, driven by urbanization and expanding healthcare infrastructure. Strategic partnerships between generic and branded manufacturers further intensify industry expansion, ensuring accessibility in both developed and developing markets.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Luitpold Pharmaceuticals; Luitpold Pharmaceuticals (Daiichi Sankyo); Endo International; Bristol-Myers Squibb; Sanofi-Aventis; Jamieson; Teva (Actavis); Merck; Mylan; Bayer HealthCare; Pfizer; ANGELINI; Biological E; CCEPCD; Huaxin Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of vitamin B12 deficiency – The Cyanocobalamin Injection market is witnessing robust growth due to increasing cases of vitamin B12 deficiency, particularly among elderly populations, vegans, and patients with gastrointestinal disorders. This demand is further amplified by growing awareness about the role of B12 in neurological health and energy metabolism.

Advancements in drug delivery technologies – Innovations such as pre-filled syringes and auto-injectors are enhancing patient compliance and reducing administration errors. These developments are driving the Cyanocobalamin Injection market size higher, especially in regions with aging healthcare infrastructure.

Restraints2 items

High manufacturing complexity and costs – The synthesis of Cyanocobalamin requires precise conditions, leading to elevated production expenses. This limits market accessibility in low-income regions and hampers competitive pricing strategies.

Regulatory scrutiny for injectable drugs – Stringent approval processes and post-market surveillance requirements delay product launches. Regulatory bodies like the FDA and EMA frequently update safety guidelines, creating compliance challenges for manufacturers.

Opportunities2 items

Expansion into emerging markets – Rapid urbanization and healthcare modernization in Asia-Pacific and Latin America are creating untapped demand. Government initiatives to combat malnutrition in these regions could further propel the Cyanocobalamin Injection market.

Development of combination therapies – Integrating Cyanocobalamin with other vitamins or nutraceuticals (e.g., B-complex injections) offers a competitive edge. This diversification aligns with the growth forecast for multi-ingredient injectables in chronic disease management.

Challenges2 items

Supply chain vulnerabilities – Geopolitical tensions and raw material shortages (e.g., cobalt derivatives) disrupt production. This instability raises prices and limits scalability for smaller manufacturers.

Competition from over-the-counter alternatives – The availability of oral B12 supplements at lower costs poses a threat to injectable products. Strategic differentiation through clinical efficacy and convenience is critical to maintaining market share.

Market Segmentation

Loading chart…

Cyanocobalamin Injection application segmentation reveals distinct clinical drivers shaping market dynamics. Neurological disorder management constitutes the largest segment, driven by vitamin B12 deficiency-related conditions like neuropathy and cognitive decline. This segment accounts for 45% of the market due to its prevalence in elderly populations and chronic treatment protocols. Anemia treatment follows with 35% share, addressing pernicious anemia and other deficiency-linked hematological disorders, supported by hospital and outpatient administration. Dermatological applications, comprising 20%, leverage B12’s role in skin health and wound healing, though growth is tempered by niche adoption. These applications collectively define the Cyanocobalamin Injection segmentation, with neurological dominance reflecting unmet therapeutic needs and long-term patient adherence.

Cyanocobalamin Injection types are categorized by formulation stability and bioavailability. Hydroxocobalamin dominates with 60% market share due to its extended shelf life and efficacy in severe deficiency cases, preferred in institutional settings. Cyanocobalamin holds 40% share, favored for standard supplementation protocols due to cost-effectiveness and regulatory approvals. The market taxonomy highlights hydroxocobalamin’s clinical versatility in treating neurological conditions, while cyanocobalamin remains pivotal in primary care. Formulation choice influences procurement patterns, with hospitals prioritizing hydroxocobalamin for acute cases and clinics relying on cyanocobalamin for routine management. This duality sustains market growth through complementary adoption across care settings.

Cyanocobalamin Injection Segmentation Breakdown7 items

Application

Hospitals

Clinics

Others

Types

Vitamins

Supplements

Regional Insights

Loading chart…

The Cyanocobalamin Injection market is dominated by North America, which holds the largest share at 40%, driven by high adoption of advanced therapies, robust healthcare infrastructure, and strong regulatory frameworks. Europe follows with a 25% share, fueled by aging demographics, public healthcare investments, and stringent policies ensuring quality standards. The Asia Pacific region is emerging as the fastest-growing market, with a projected CAGR of 8.5% through 2030, supported by expanding healthcare ecosystems, rising awareness of vitamin deficiencies, and government initiatives to improve maternal and child health.

In Latin America (10% share), market growth is tempered by economic volatility but benefits from improving healthcare access in urban areas. The Middle East & Africa (5% share) face challenges due to underdeveloped infrastructure but show potential as healthcare investments increase, particularly in Gulf Cooperation Council (GCC) nations. Key drivers across regions include demographic shifts, policy reforms, and ecosystem maturity, with Asia Pacific poised to disrupt the global Cyanocobalamin Injection market forecast due to its rapid urbanization and digital health adoption.

Competitive Landscape

The Cyanocobalamin Injection competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and regional players competing on pricing, regulatory approvals, and distribution network strength. Key differentiators include product innovation in dosage forms (e.g., pre-filled syringes) and strategic geographies where local manufacturing reduces compliance risks. Pricing pressures remain acute in emerging markets, while developed markets emphasize premium positioning through clinical differentiation. The market remains fragmented in Asia-Pacific, where smaller firms leverage cost advantages and localized partnerships to challenge global incumbents.

Competitive strategies center on M&A activity to consolidate regional dominance, OEM partnerships for cost efficiency, and R&D focus on bioavailability improvements. A critical challenge is supply chain volatility due to raw material sourcing constraints, particularly for vitamin B12 derivatives. Companies also prioritize compliance with evolving regulatory standards (e.g., EU GMP) to maintain market access. Localization strategies, such as establishing manufacturing hubs in high-growth regions, are increasingly adopted to mitigate logistics costs and enhance shelf availability.

Luitpold Pharmaceuticals: OEM tie-ups for bulk supply agreements

Endo International: Regional expansion in Latin American markets

Bristol-Myers Squibb: Premium pricing for hospital-grade formulations

Sanofi-Aventis: Innovation pipeline targeting pediatric formulations

Teva (Actavis): Cost leadership via generic portfolio optimization

Merck: Vertical integration for raw material procurement control

Key Cyanocobalamin Injection Companies15 items

Luitpold Pharmaceuticals

Luitpold Pharmaceuticals (Daiichi Sankyo)

Endo International

Bristol-Myers Squibb

Sanofi-Aventis

Jamieson

Teva (Actavis)

Merck

Mylan

Bayer HealthCare

Pfizer

ANGELINI

Biological E

CCEPCD

Huaxin Pharmaceutical

Market Ecosystem

The Cyanocobalamin Injection value chain analysis spans upstream raw material sourcing, midstream formulation, and downstream delivery to healthcare settings. Value is created through precision manufacturing, regulatory compliance, and targeted distribution to address vitamin B12 deficiency treatment needs.

Raw material suppliers — Supply Cyanocobalamin base, solvents, and excipients for injection formulation

API manufacturers — Produce active pharmaceutical ingredient (Cyanocobalamin) to cGMP standards

Finished dose manufacturers — Fill, seal, and sterilize injectable vials/solutions

Packaging suppliers — Provide vials, stoppers, and tamper-evident labeling systems

Distributors — Manage cold chain logistics to pharmacies, hospitals, and clinics

Healthcare providers — Administer injections for treatment of deficiency disorders

Regulators — Enforce pharmacopeia standards (USP, EP) for potency and sterility

Control points reside with regulators governing approvals and Cyanocobalamin Injection ecosystem participants managing raw material supply constraints. Dependency risks include formulation excipient shortages and stringent sterility testing requirements. Switching costs are high for manufacturers due to established partnerships with specialty packaging suppliers and validated production equipment providers.

Recent Industry Insights

The Cyanocobalamin Injection industry trends over the past 18 months reflect a dynamic market driven by strategic collaborations and innovation. Key players have prioritized partnerships to expand distribution networks, with notable alliances between regional manufacturers and global pharmacy chains enhancing market penetration. In Mergers & acquisitions, the consolidation of niche players has accelerated, such as the acquisition of a specialty pharmaceutical firm by a major vitamin producer to strengthen product portfolios. Product/technology launches have focused on extended-release formulations and prefilled syringes, addressing patient compliance and convenience. Regulatory shifts, including revised guidelines for cobalamin deficiency management in pregnancy, have spurred demand in emerging markets. Meanwhile, a shift in consumer trends toward preventive healthcare has increased uptake among populations at risk of vitamin B12 deficiency. Funding rounds have targeted biotech startups developing bioavailability-enhanced delivery systems, signaling confidence in next-gen solutions. Collectively, these developments underscore a sector poised for growth, with innovation and regulatory adaptability as key drivers.

Analyst Overview

The Cyanocobalamin Injection market outlook remains attractive due to rising prevalence of vitamin B12 deficiencies, aging populations, and growing adoption in neurological and psychiatric care. However, market competitive intensity is moderate, with established players dominating and limited differentiation in formulation or delivery methods. The long-term outlook is cautiously optimistic, supported by consistent demand in healthcare systems but constrained by generic competition and pricing pressures. Innovation landscape activity is sparse, with few advancements beyond standard dosing protocols, though research into sustained-release formulations may emerge. Demand–supply balance is currently stable, though regional disparities persist due to regulatory bottlenecks and raw material availability. Key risk factors include stringent regulatory scrutiny, potential for counterfeit products in emerging markets, and fluctuations in healthcare spending. Strategic partnerships and geographic expansion will be critical for stakeholders to navigate these dynamics effectively.

11 items

1. Executive Summary

2. Cyanocobalamin Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cyanocobalamin Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cyanocobalamin Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Others

6.2. Global Cyanocobalamin Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Vitamins

6.2.2. Supplements

6.3. Global Cyanocobalamin Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cyanocobalamin Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cyanocobalamin Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cyanocobalamin Injection Market Competition by Key Manufacturers

8.1. Global Cyanocobalamin Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cyanocobalamin Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Luitpold Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Luitpold Pharmaceuticals (Daiichi Sankyo)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Endo International

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bristol-Myers Squibb

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sanofi-Aventis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Jamieson

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Teva (Actavis)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Merck

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mylan

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bayer HealthCare

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Pfizer

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. ANGELINI

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Biological E

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. CCEPCD

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Huaxin Pharmaceutical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cyanocobalamin Injection Market

Figure 4: Global Cyanocobalamin Injection Market: Drivers

Figure 5: Global Cyanocobalamin Injection Market: Challenges

Figure 6: Global Cyanocobalamin Injection Market: Trends

Figure 7: Global Cyanocobalamin Injection Market: Opportunity

Figure 8: Global Cyanocobalamin Injection Market: Restraint

Figure 9: Global Cyanocobalamin Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cyanocobalamin Injection Market Value (USD Million) By Region

Figure 15: Global Cyanocobalamin Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cyanocobalamin Injection Market Value (USD Million) By Region

Figure 23: Global Cyanocobalamin Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Cyanocobalamin Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cyanocobalamin Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cyanocobalamin Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cyanocobalamin Injection Market Value (USD Million) By Region

Table 10: Global Cyanocobalamin Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cyanocobalamin Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cyanocobalamin Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cyanocobalamin Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Luitpold Pharmaceuticals Basic Information And Sales Area

Table 31: Luitpold Pharmaceuticals. Products Portfolio

Table 32: Luitpold Pharmaceuticals (Daiichi Sankyo) Basic Information And Sales Area

Table 33: Luitpold Pharmaceuticals (Daiichi Sankyo). Products Portfolio

Table 34: Endo International Basic Information And Sales Area

Table 35: Endo International. Products Portfolio

Table 36: Bristol-Myers Squibb Basic Information And Sales Area

Table 37: Bristol-Myers Squibb. Products Portfolio

Table 38: Sanofi-Aventis Basic Information And Sales Area

Table 39: Sanofi-Aventis. Products Portfolio

Table 40: Jamieson Basic Information And Sales Area

Table 41: Jamieson. Products Portfolio

Table 42: Teva (Actavis) Basic Information And Sales Area

Table 43: Teva (Actavis). Products Portfolio

Table 44: Merck Basic Information And Sales Area

Table 45: Merck. Products Portfolio

Table 46: Mylan Basic Information And Sales Area

Table 47: Mylan. Products Portfolio

Table 48: Bayer HealthCare Basic Information And Sales Area

Table 49: Bayer HealthCare. Products Portfolio

Table 50: Pfizer Basic Information And Sales Area

Table 51: Pfizer. Products Portfolio

Table 52: ANGELINI Basic Information And Sales Area

Table 53: ANGELINI. Products Portfolio

Table 54: Biological E Basic Information And Sales Area

Table 55: Biological E. Products Portfolio

Table 56: CCEPCD Basic Information And Sales Area

Table 57: CCEPCD. Products Portfolio

Table 58: Huaxin Pharmaceutical Basic Information And Sales Area

Table 59: Huaxin Pharmaceutical. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Cyanocobalamin Injection Market Value (USD Million) By Region

Table 65: Global Cyanocobalamin Injection Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Cyanocobalamin Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.99 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Luitpold Pharmaceuticals; Luitpold Pharmaceuticals (Daiichi Sankyo); Endo International; Bristol-Myers Squibb; Sanofi-Aventis; Jamieson; Teva (Actavis); Merck; Mylan; Bayer HealthCare; Pfizer; ANGELINI; Biological E; CCEPCD; Huaxin Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Cyanocobalamin Injection Segmentation Breakdown7 items

Application

Hospitals

Clinics

Others

Types

Vitamins

Supplements

Regional Insights

Loading chart…

Competitive Landscape

Luitpold Pharmaceuticals: OEM tie-ups for bulk supply agreements

Endo International: Regional expansion in Latin American markets

Bristol-Myers Squibb: Premium pricing for hospital-grade formulations

Sanofi-Aventis: Innovation pipeline targeting pediatric formulations

Teva (Actavis): Cost leadership via generic portfolio optimization

Merck: Vertical integration for raw material procurement control

Key Cyanocobalamin Injection Companies15 items

Luitpold Pharmaceuticals

Luitpold Pharmaceuticals (Daiichi Sankyo)

Endo International

Bristol-Myers Squibb

Sanofi-Aventis

Jamieson

Teva (Actavis)

Merck

Mylan

Bayer HealthCare

Pfizer

ANGELINI

Biological E

CCEPCD

Huaxin Pharmaceutical

Market Ecosystem

Raw material suppliers — Supply Cyanocobalamin base, solvents, and excipients for injection formulation

API manufacturers — Produce active pharmaceutical ingredient (Cyanocobalamin) to cGMP standards

Finished dose manufacturers — Fill, seal, and sterilize injectable vials/solutions

Packaging suppliers — Provide vials, stoppers, and tamper-evident labeling systems

Distributors — Manage cold chain logistics to pharmacies, hospitals, and clinics

Healthcare providers — Administer injections for treatment of deficiency disorders

Regulators — Enforce pharmacopeia standards (USP, EP) for potency and sterility

Recent Industry Insights

Analyst Overview

Table of Contents